Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 3.16.1 For systems used or deployed by the investigator/institution: Difference between revisions

From GxPlex

Jump to: navigation, search
m 1 revision imported
gxplex>GxPlexBot
Import from GxPlex Excel
Line 13: Line 13:
{{:Document:ICH ICH E6 Guideline R3 (2025)}}
{{:Document:ICH ICH E6 Guideline R3 (2025)}}


{| class="gplx-infobox"
{| class="wikitable gplx-infobox"
|-
|-
! colspan="2" class="gplx-infobox-header" | Reference Details
! colspan="2" class="gplx-infobox-header" | Reference Details

Revision as of 15:27, 29 June 2026



Document information
Reference ICH ICH E6 Guideline R3 (2025)
Validity area ICH
Scope(s) HM
Document name ICH E6 Guideline
Version / Revision R3 (2025)
Status Current
Document type International guideline
Language(s) EN
Description GUIDELINE FOR GOOD CLINICAL PRACTICE
Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors


Reference Details
Scope G
Document part III. Annex 1

3.16.1 For systems used or deployed by the investigator/institution

Language EN
Original entry by Florian Adragna
Contributors
Tags (EN)
Tags (original language)
Tags (FR)
Comment Data handling procedures in clinical trials

Content

3.16 Data and Records 3.16.1 Data Handling [...] For systems used or deployed by the investigator/institution: [...] (vii) In situations where clinical practice computerised systems are being considered for use in clinical trials (e.g., electronic health records or imaging systems used or deployed by the investigator/institution), these systems should be assessed for their fitness for purpose in the context of the trial;

(viii) The assessment should be performed before being used in the trial and should be proportionate to the importance of the data managed in the system. Factors such as data security (including measures for backup), user management and audit trails, which help ensure the protection of confidentiality and integrity of the trial data, should be considered as appropriate;